The treatment of established murine collagen-induced arthritis with a TNFR1-selective antagonistic mutant TNF

Biomaterials

Volumn 30, Issue 34, 2009, Pages 6638-6647

  Shibata, Hiroko ^a,b   Yoshioka, Yasuo ^c   Abe, Yasuhiro ^a   Ohkawa, Akiko ^a   Nomura, Tetsuya ^a,c   Minowa, Kyoko ^a   Mukai, Yohei ^a,c   Nakagawa, Shinsaku ^c   Taniai, Madoka ^d   Ohta, Tsunetaka ^d   Kamada, Haruhiko ^a,c   Tsunoda, Shin ichi ^a,c   Tsutsumi, Yasuo ^a,c  

^a NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^b NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d HAYASHIBARA BIOCHEMICAL LABORATORIES INC   (Japan)

Author keywords

Cytokine receptors; Cytokines; Rheumatoid arthritis; Tumor necrosis factor

Indexed keywords

ANTI-INFLAMMATORY DRUGS; ANTI-INFLAMMATORY EFFECTS; COLLAGEN-INDUCED ARTHRITIS; CYTOKINE RECEPTORS; CYTOKINES; IN-VIVO; RHEUMATOID ARTHRITIS; SELECTIVE INHIBITION; THERAPEUTIC EFFECTS; THERAPEUTIC PROTOCOLS; TUMOR NECROSIS FACTOR; VIRAL INFECTIONS;

COLLAGEN; GLYCOPROTEINS; HEALTH; MACROPHAGES; POLYETHYLENE OXIDES; TUMORS;

POLYETHYLENE GLYCOLS;

COLLAGEN; ETANERCEPT; INTERLEUKIN 1BETA; MACROGOL; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR 1 ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG HALF LIFE; DRUG STABILITY; FEMALE; MALE; MOUSE; MUTANT; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; VIRUS INFECTION; VIRUS REACTIVATION;

ANIMALS; ARTHRITIS, EXPERIMENTAL; CELL PROLIFERATION; COLLAGEN; FEMALE; MICE; MICE, INBRED STRAINS; MUTATION; OSTEOCLASTS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SURFACE PLASMON RESONANCE; TUMOR NECROSIS FACTOR-ALPHA;

MURINAE;

EID: 70349785146     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2009.08.041     Document Type: Article

References (49)

1. Lee D.M., and Weinblatt M.E. Rheumatoid arthritis. Lancet 358 9285 (2001 Sep 15) 903-911
2. Chu C.Q., Field M., Feldmann M., and Maini R.N. Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 34 9 (1991 Sep) 1125-1132
3. Feldmann M., Brennan F.M., and Maini R.N. Rheumatoid arthritis. Cell 85 3 (1996 May 3) 307-310
4. Maury C.P., and Teppo A.M. Cachectin/tumour necrosis factor-alpha in the circulation of patients with rheumatic disease. Int J Tissue React 11 4 (1989) 189-193
5. Feldmann M., and Maini R.N. Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med 9 10 (2003 Oct) 1245-1250
6. Thorbecke G.J., Shah R., Leu C.H., Kuruvilla A.P., Hardison A.M., and Palladino M.A. Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. Proc Natl Acad Sci U S A 89 16 (1992 Aug 15) 7375-7379
7. Williams R.O., Feldmann M., and Maini R.N. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 89 20 (1992 Oct 15) 9784-9788
8. Moreland L.W., Schiff M.H., Baumgartner S.W., Tindall E.A., Fleischmann R.M., Bulpitt K.J., et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 130 6 (1999 Mar 16) 478-486
9. Chung E.S., Packer M., Lo K.H., Fasanmade A.A., and Willerson J.T. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107 25 (2003 Jul 1) 3133-3140
10. Mohan N., Edwards E.T., Cupps T.R., Oliverio P.J., Sandberg G., Crayton H., et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 44 12 (2001 Dec) 2862-2869
11. Shakoor N., Michalska M., Harris C.A., and Block J.A. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 359 9306 (2002 Feb 16) 579-580
12. Gomez-Reino J.J., Carmona L., Valverde V.R., Mola E.M., and Montero M.D. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48 8 (2003 Aug) 2122-2127
13. Lubel J.S., Testro A.G., and Angus P.W. Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management. Intern Med J 37 10 (2007 Oct) 705-712
14. Brown S.L., Greene M.H., Gershon S.K., Edwards E.T., and Braun M.M. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 46 12 (2002 Dec) 3151-3158
15. Mori L., Iselin S., De Libero G., and Lesslauer W. Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice. J Immunol 157 7 (1996 Oct 1) 3178-3182
16. Butler D.M., Malfait A.M., Mason L.J., Warden P.J., Kollias G., Maini R.N., et al. DBA/1 mice expressing the human TNF-alpha transgene develop a severe, erosive arthritis: characterization of the cytokine cascade and cellular composition. J Immunol 159 6 (1997 Sep 15) 2867-2876
17. Keffer J., Probert L., Cazlaris H., Georgopoulos S., Kaslaris E., Kioussis D., et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 10 13 (1991 Dec) 4025-4031
18. Kim E.Y., Priatel J.J., Teh S.J., and Teh H.S. TNF receptor type 2 (p75) functions as a costimulator for antigen-driven T cell responses in vivo. J Immunol 176 2 (2006 Jan 15) 1026-1035
19. Kim E.Y., and Teh H.S. TNF type 2 receptor (p75) lowers the threshold of T cell activation. J Immunol 167 12 (2001 Dec 15) 6812-6820
20. Grell M., Becke F.M., Wajant H., Mannel D.N., and Scheurich P. TNF receptor type 2 mediates thymocyte proliferation independently of TNF receptor type 1. Eur J Immunol 28 1 (1998 Jan) 257-263
21. Grell M., Douni E., Wajant H., Lohden M., Clauss M., Maxeiner B., et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83 5 (1995 Dec 1) 793-802
22. Olleros M.L., Guler R., Corazza N., Vesin D., Eugster H.P., Marchal G., et al. Transmembrane TNF induces an efficient cell-mediated immunity and resistance to Mycobacterium bovis bacillus Calmette-Guerin infection in the absence of secreted TNF and lymphotoxin-alpha. J Immunol 168 7 (2002 Apr 1) 3394-3401
23. Saunders B.M., Tran S., Ruuls S., Sedgwick J.D., Briscoe H., and Britton W.J. Transmembrane TNF is sufficient to initiate cell migration and granuloma formation and provide acute, but not long-term, control of Mycobacterium tuberculosis infection. J Immunol 174 8 (2005 Apr 15) 4852-4859
24. Kollias G., and Kontoyiannis D. Role of TNF/TNFR in autoimmunity: specific TNF receptor blockade may be advantageous to anti-TNF treatments. Cytokine Growth Factor Rev 13 4-5 (2002 Aug-Oct) 315-321
25. Shibata H., Yoshioka Y., Ohkawa A., Minowa K., Mukai Y., Abe Y., et al. Creation and X-ray structure analysis of the tumor necrosis factor receptor-1-selective mutant of a tumor necrosis factor-alpha antagonist. J Biol Chem 283 2 (2008 Jan 11) 998-1007
26. Shibata H., Yoshioka Y., Ohkawa A., Abe Y., Nomura T., Mukai Y., et al. The therapeutic effect of TNFR1-selective antagonistic mutant TNF-alpha in murine hepatitis models. Cytokine 44 2 (2008 Nov) 229-233
27. Shibata H., Yoshioka Y., Ikemizu S., Kobayashi K., Yamamoto Y., Mukai Y., et al. Functionalization of tumor necrosis factor-alpha using phage display technique and PEGylation improves its antitumor therapeutic window. Clin Cancer Res 10 24 (2004 Dec 15) 8293-8300
28. Yamamoto Y., Tsutsumi Y., Yoshioka Y., Nishibata T., Kobayashi K., Okamoto T., et al. Site-specific PEGylation of a lysine-deficient TNF-alpha with full bioactivity. Nat Biotechnol 21 5 (2003 May) 546-552
29. Yoshioka Y., Tsutsumi Y., Ikemizu S., Yamamoto Y., Shibata H., Nishibata T., et al. Optimal site-specific PEGylation of mutant TNF-alpha improves its antitumor potency. Biochem Biophys Res Commun 315 4 (2004 Mar 19) 808-814
30. Tsutsumi Y., Kihira T., Tsunoda S., Kanamori T., Nakagawa S., and Mayumi T. Molecular design of hybrid tumour necrosis factor alpha with polyethylene glycol increases its anti-tumour potency. Br J Cancer 71 5 (1995 May) 963-968
31. Joosten L.A., Helsen M.M., van de Loo F.A., and van den Berg W.B. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum 39 5 (1996 May) 797-809
32. Larsson E., Erlandsson Harris H., Larsson A., Mansson B., Saxne T., and Klareskog L. Corticosteroid treatment of experimental arthritis retards cartilage destruction as determined by histology and serum COMP. Rheumatology (Oxford) 43 4 (2004 Apr) 428-434
33. Koizumi N., Kawabata K., Sakurai F., Watanabe Y., Hayakawa T., and Mizuguchi H. Modified adenoviral vectors ablated for coxsackievirus-adenovirus receptor, alphav integrin, and heparan sulfate binding reduce in vivo tissue transduction and toxicity. Hum Gene Ther 17 3 (2006 Mar) 264-279
34. Redlich K., Hayer S., Ricci R., David J.P., Tohidast-Akrad M., Kollias G., et al. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 110 10 (2002 Nov) 1419-1427
35. Zhang Y.H., Heulsmann A., Tondravi M.M., Mukherjee A., and Abu-Amer Y. Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J Biol Chem 276 1 (2001 Jan 5) 563-568
36. Zhou G.Q., Zhao N., Zhang H., Jia H.W., Zhang W.D., Zhao L.H., et al. Effect of Gui Zhi decoction on enteric mucosal immune in mice with collagen-induced arthritis. World J Gastroenterol 11 34 (2005 Sep 14) 5373-5376
37. Kafrouni M.I., Brown G.R., and Thiele D.L. The role of TNF-TNFR2 interactions in generation of CTL responses and clearance of hepatic adenovirus infection. J Leukoc Biol 74 4 (2003 Oct) 564-571
38. Firestein G.S. Evolving concepts of rheumatoid arthritis. Nature 423 6937 (2003 May 15) 356-361
39. Lee D.M., Kiener H.P., Agarwal S.K., Noss E.H., Watts G.F., Chisaka O., et al. Cadherin-11 in synovial lining formation and pathology in arthritis. Science 315 5814 (2007 Feb 16) 1006-1010
40. Asagiri M., Hirai T., Kunigami T., Kamano S., Gober H.J., Okamoto K., et al. Cathepsin K-dependent toll-like receptor 9 signaling revealed in experimental arthritis. Science 319 5863 (2008 Feb 1) 624-627
41. Joosten L.A., Helsen M.M., Saxne T., van De Loo F.A., and Heinegard D. van Den Berg WB. IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. J Immunol 163 9 (1999 Nov 1) 5049-5055
42. Tada Y., Ho A., Koarada S., Morito F., Ushiyama O., Suzuki N., et al. Collagen-induced arthritis in TNF receptor-1-deficient mice: TNF receptor-2 can modulate arthritis in the absence of TNF receptor-1. Clin Immunol 99 3 (2001 Jun) 325-333
43. Peschon J.J., Torrance D.S., Stocking K.L., Glaccum M.B., Otten C., Willis C.R., et al. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol 160 2 (1998 Jan 15) 943-952
44. Chen X., Baumel M., Mannel D.N., Howard O.M., and Oppenheim J.J. Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4 + CD25 + T regulatory cells. J Immunol 179 1 (2007 Jul 1) 154-161
45. Winthrop K.L. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2 11 (2006 Nov) 602-610
46. Nathan D.M., Angus P.W., and Gibson P.R. Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach. J Gastroenterol Hepatol 21 9 (2006 Sep) 1366-1371
47. Chan F.K., Shisler J., Bixby J.G., Felices M., Zheng L., Appel M., et al. A role for tumor necrosis factor receptor-2 and receptor-interacting protein in programmed necrosis and antiviral responses. J Biol Chem 278 51 (2003 Dec 19) 51613-51621
48. Zalevsky J., Secher T., Ezhevsky S.A., Janot L., Steed P.M., O'Brien C., et al. Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection. J Immunol 179 3 (2007 Aug 1) 1872-1883
49. Spohn G., Guler R., Johansen P., Keller I., Jacobs M., Beck M., et al. A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis. J Immunol 178 11 (2007 Jun 1) 7450-7457